CTLA4 and melanoma: Similar results were described by van der Kooij et al. (2021) who investigated the response of anti-CTLA-4, anti-PD-1, or a combination therapy in advanced melanoma, highlighting that among patients with pre-existing IBD, severe colitis and toxicity more frequently occurred, thus requiring an early discontinuation of the treatment [93].